Artikler

Interview by DermTalks
DermTalks is a project led with a board of dermatologists and intended to address current challenges, data gaps and emerging trends in dermatology across North-European countries.

Speaker: Prof. Mette Deleuran, Associate Professor and Chair of the Department of Dermatology and Venereology, Aarhus University Hospital, Denmark.

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.^1-4 

The clinical benefits of early detection of T1D are being highlighted.^3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.^1,2

Autoimmune Type 1 diabetes (T1D) is undergoing a fundamental transformation in how the medical community approaches diagnosis and care.

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene, resulting in deficient activity of the enzyme acid β glucosidase.

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life (QoL), often requiring recurring systemic corticosteroid use and repeated sinus surgery.

The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.^1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.^2,3